How important is it that your doctor use mediastinoscopy vs. bronchoscopy to diagnosis your lung cancer? Patient Power guest host, Janet Freeman-Daily speaks with lung cancer specialist, Dr. David Odell of Robert H. Lurie Comprehensive Cancer Center on his opinion of these two scoping mechanisms. Dr. Odell explains the differences...
Read More
Transcript Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Janet...
Read More
In a nutshell This trial examined whether altering the recommended dose of chemotherapy drugs during treatment was beneficial to patients. This trial concluded that altering doses of paclitaxel (Taxol) during chemotherapy could be beneficial to reduce neuropathy in patients with advanced non-small-cell lung cancer. Some...
Read MoreIn a nutshell This trial examined different surgical techniques to treat early stage non-small-stage lung cancer. The authors concluded that there was no difference in effectiveness between three different surgical techniques for patients with early stage NSCLC. Some background Early-stage non-small cell lung cancer (NSCLC) is commonly...
Read MoreIn a nutshell This phase I/II trial aims to determine the effectiveness and safety of combining hypofractionated proton therapy with chemotherapy in treating patients with stage II or stage III non-small-cell lung cancer (NSCLC). The main outcome of the trial will be maximum tolerated dose (MTD – highest dose of the treatment that does not cause...
Read More
In a nutshell This phase I/IB trial aims to determine whether combining MEK162(ARRY-162) and erlotinib (Tarceva) is safe and effective at treating patients with stage IV non-small cell lung cancer (NSCLC) with KRAS or EGFR mutations and no curative treatment options. The main outcome of the trial will be maximum tolerated dose (MTD – highest dose...
Read More
In a nutshell The authors examined the use of local consolidative therapy to treat patients with advanced NSCLC with few metastases after first line treatment. They concluded that this is more effective than maintenance therapy alone for this specific group of patients. Some background Previous studies that examined treatment failure after first...
Read More
In a nutshell The review summarizes recent clinical trials and provides up to date guidelines on the detection, treatment and follw-up of advanced non-small-cell lung cancer (NSCLC). Some background Lung cancer is the leading cause of cancer-related deaths globally with NSCLC as the most common subtype of lung cancer. The success...
Read More
Dawn Goo is a waitress, former comedian, breast cancer survivor and is now under treatment for Non Hodgkins Lymphoma. She lives in El Paso, Texas. This is a post from her Facebook page which is gathering momentum in social media among people who have experienced cancer, especially those who are dealing with Stage 4 disease. DAMN IT DAWN! WE ONLY WANT...
Read More
In a nutshell The authors aimed to determine whether SBRT is an effective and tolerable treatment for elderly patients with inoperable non-small cell lung cancer (NSCLC). They concluded that the treatment is both effective and safe. Some background In elderly patients with NSCLC, surgery is not always the best option. There is often a higher rate...
Read MoreIn a nutshell This study examined whether stereotactic body radiotherapy (SBRT) is a safe and effective treatment for patients with non-small-cell lung cancer (NSCLC) with tumors measuring over 5 cm. The authors concluded that SBRT is safe and effective for these patients. Some background Some patients with NSCLC are ineligible for...
Read MoreIn a nutshell This trial examined whether the immunotherapy atezolizumab (Tecentriq) is more effective than docetaxel (Taxotere) at treating non-small-cell lung cancer that has progressed passed first line treatment. The authors concluded that atezolizumab provided an overall survival benefit compared to docetaxel. Some background Docetaxel is the...
Read More
